Immunoglobulin constant region Fc receptor binding agents
US-9926362-B2 · Mar 27, 2018 · US
Intradermal administration of immunoglobulin G preparation
US12091444B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12091444-B2 |
| Application number | US-202016805425-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 28, 2020 |
| Priority date | Feb 5, 2016 |
| Publication date | Sep 17, 2024 |
| Grant date | Sep 17, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method for administration of an IgG preparation by an intradermal (ID) route to a subject includes loading with a volume of the IgG preparation an ID delivery device including needles, applying the device to a skin delivery site, using the device to allow dermal penetration of the needles, delivering the volume of the IgG preparation at the skin delivery site, and removing the injection delivery device. The method can be used in the treatment of a disease, such as an immunodeficiency.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating a disease selected from the group consisting of an immunodeficiency, a disease of autoimmune origin, or combinations thereof in a subject in need thereof, the method comprising: administering a pooled human plasma-derived intravenous IgG antibody solution further comprising IgA and IgM to the subject using an ID delivery device comprising needles, wherein the ID delivery device is applied to a skin delivery site to allow dermal penetration of the needles such that the pooled human plasma-derived intravenous IgG antibody solution further comprising IgA and IgM is delivered at the skin delivery site, wherein the pooled human plasma-derived IVIG antibody preparation is about 2 mL to about 8 mL in volume with a pH of about 6.5, and has IgG concentration of about 16.5% to about 20% (w/v). 2. The method according to claim 1 , wherein the subject is a pediatric patient. 3. The method according to claim 1 , wherein the subject is a non-pediatric patient. 4. The method according to claim 1 , wherein the immunodeficiency is one of a primary immunodeficiency, a secondary immunodeficiency or an acquired immunodeficiency.
Assignees
Inventors
Classifications
Other apparatus for introducing media into the body (for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30); Percutany, i.e. introducing medicines into the body by diffusion through the skin (salt baths A61H33/04) · CPC title
- A61K9/0021Primary
Intradermal administration, e.g. through microneedle arrays or needleless injectors · CPC title
Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title
comprising antibodies · CPC title
characterised by the route of administration · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12091444B2 cover?
- A method for administration of an IgG preparation by an intradermal (ID) route to a subject includes loading with a volume of the IgG preparation an ID delivery device including needles, applying the device to a skin delivery site, using the device to allow dermal penetration of the needles, delivering the volume of the IgG preparation at the skin delivery site, and removing the injection deliv…
- Who is the assignee on this patent?
- Grifols Worldwide Operations Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K9/0021. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).